
Marion Cubitt is a leading expert on VHH antibodies, and is currently Director of Discovery at Isogenica.
After completing her PhD in Biochemistry from the University of Cambridge, Marion developed the world’s first clinically effective oral biologic – a bi-specific VHH engineered for resistance to intestinal proteases.
Over her 5 years at Isogenica, Marion continues to share her expertise on end-to-end VHH product development, from complex discovery strategies to advanced engineering and novel manufacturing approaches.